SCHEDULE 13G/A: Frazier Life Sciences Funds Disclose Over 10% Stake in Trevi Therapeutics
Beneficial Ownership Report (Schedule 13G Amendment)
Frazier Life Sciences Public Fund, L.P. and affiliated entities, along with key individuals, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 10.6% in Trevi Therapeutics, Inc.
Summary
- Frazier Life Sciences Public Fund, L.P. and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) beneficially own 8,508,021 shares, representing 8.8% of Trevi Therapeutics, Inc. common stock.
- Frazier Life Sciences X, L.P. and its related entities (FHMLS X, L.P. and FHMLS X, L.L.C.) beneficially own 397,309 shares, representing 0.4% of Trevi Therapeutics, Inc. common stock.
- Frazier Life Sciences XI, L.P. and its related entities (FHMLS XI, L.P. and FHMLS XI, L.L.C.) beneficially own 1,354,079 shares, representing 1.4% of Trevi Therapeutics, Inc. common stock.
- Key individuals James N. Topper and Patrick J. Heron each beneficially own an aggregate of 10,259,409 shares, representing 10.6% of the outstanding common stock, through their shared voting and investment power over the combined holdings of the Frazier Life Sciences funds.
- Albert Cha and James Brush each beneficially own 8,508,021 shares (8.8%) through their shared voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.
- Daniel Estes beneficially owns 1,354,079 shares (1.4%) through his shared voting and investment power over the shares held by Frazier Life Sciences XI, L.P.
- The percentage ownership is calculated based on 96,682,229 shares of Common Stock outstanding as of March 14, 2025, as reported in Trevi Therapeutics, Inc.'s Annual Report on Form 10-K.
Sentiment
Score: 5
Explanation: The document is a standard beneficial ownership disclosure (Schedule 13G Amendment) and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook. It merely reports a significant ownership stake.
Positives
- The filing indicates a significant and continued investment by Frazier Life Sciences, a prominent life sciences fund, which could be interpreted as a vote of confidence in Trevi Therapeutics, Inc.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Stakeholder Impact
- The disclosure of a significant 10.6% ownership stake by Frazier Life Sciences, a reputable life sciences investment group, may be viewed positively by other shareholders as a sign of institutional confidence in Trevi Therapeutics.
- The potential for the investor group to nominate directors, as indicated by the certification, suggests a future possibility of influencing corporate governance and strategic direction, which could impact existing management and other stakeholders.
Key Dates
| Date | Description |
|---|---|
| March 14, 2025 | Date of Trevi Therapeutics, Inc.'s Annual Report on Form 10-K, which provided the outstanding share count used for ownership percentage calculation. |
| March 31, 2025 | Date of event which required the filing of this Schedule 13G Amendment No. 4. |
| May 15, 2025 | Filing date of the Schedule 13G Amendment No. 4. |
Recommendation
holdKeywords
Trevi Therapeutics, Frazier Life Sciences, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Institutional Ownership, Biotech, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.